An Analysis of the SALT 1 and SALT 2 Studies

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, discusses the results of the SALT 1 and SALT 2 studies, which measured the efficacy of tolvaptan (Samsca) in patients with euvolemic and hypervolemic hyponatremia.

Clinical Pearls:

• The SALT 1 and SALT 2 studies, which looked at the efficacy of tolvaptan (Samsca), found that there was a statically significant improvement in patients’ serum sodium levels compared to placebo after 30 days
• Most improvement occurred within the first 4 days
• Patients should be monitored in a hospital for the first four days and remain closely monitored after that to ensure that there is not an overcorrection of the serum sodium levels.